Filtered By:
Infectious Disease: Hepatitis

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 50128 results found since Jan 2013.

Screening patterns and identification of non-alcoholic fatty liver disease in obese children in canadian primary care
Conclusions: This is the first study to estimate the screening patterns of pediatric NAFLD in primary care in Canada at a national level. The study revealed low screening rates in primary care, these results will help facilitate prioritization of care and future work that could evaluate successful implementation strategies while emphasizing the role of PCPs in screening and managing pediatric NAFLD in Canadian health care setting.PMID:36944043 | DOI:10.1370/afm.20.s1.2930
Source: Annals of Family Medicine - March 21, 2023 Category: Primary Care Authors: Rebecca Theal Rachael Morkem John Queenan David Barber Source Type: research

A Comparison of Pretravel Health Care, Travel-Related Exposures, and Illnesses among Pediatric and Adult U.S. Military Beneficiaries.
Abstract We evaluated differences in pretravel care, exposures, and illnesses among pediatric and adult travelers, using a prospective, observational cohort. Eighty-one pediatric travelers were matched 1:1 with adult military dependents by travel region, destination's malaria risk, and travel duration. Pediatric travelers were more likely to have coverage for hepatitis A and B (90% versus 67% of adults; 85% versus 44%), visit friends and relatives (36% versus 16%), report mosquito bites (69% versus 44%), and have close contact with wild or domesticated animals (40% versus 20%) than adults (P < 0.05). Subjects &...
Source: The American Journal of Tropical Medicine and Hygiene - March 24, 2019 Category: Tropical Medicine Authors: Ashley DP, Fraser J, Yun H, Kunz A, Fairchok M, Tribble D, Mitra I, Johnson MD, Hickey PW, Ganesan A, Deiss RG, Lalani T, For The Idcrp TravMil Study Group Tags: Am J Trop Med Hyg Source Type: research

Transcript of podcast interview with Steve Grossman, candidate for Governor of Massachusetts
This is the transcript of my recent podcast interview with Steve Grossman, State Treasurer and Democratic candidate for Governor of Massachusetts. Visit the original post to listen to the podcast and read a summary. This is part of a series of interviews with all nine candidates for Governor. The full schedule is available here. David E. Williams: This is David Williams from The Health Business Blog. I’m speaking today with Steve Grossman, Treasurer of Massachusetts and candidate for Governor. Steven Grossman: David, I appreciate your time and look forward to the conversation. Williams: Steve, does Chapter 224 rep...
Source: Health Business Blog - March 11, 2014 Category: Health Managers Authors: David Williams Tags: Podcast Policy and politics community hospitals election Governor health care health care reform health information technology healthcare Massachusetts Steve Grossman Source Type: blogs

Mind Meets Body: Developing a Psychology Internship in a Family Medicine Residency Program (Raymond Hornyak PhD)
Mind Meets Body: Creating a Primary Care Psychology Internship in a Family Medicine Residency Program Introduction: Multiple studies have identified the benefits of providing behavioral health services to primary care patients. Decreased length of stay, fewer hospitalizations and emergency room visits, less frequent office visits, fewer prescriptions, and improvement in health outcomes have been associated with the availability of a behavioral health professional as part of an integrative primary care network. Family physicians have found behavioral health colleagues a valuable resource in which to refer their "diffi...
Source: Family Medicine Digital Resources Library (FMDRL) Recently Uploaded - November 14, 2013 Category: Primary Care Source Type: news

Sovaldi, a Quantum Leap? - Backwards to the Days Before Randomized Controlled Trials
The Sovaldi (sofosbuvir - Gilead) media circus is continuing.  The New York Times just reported that sales of the new drug for hepatitis C were about $3.5 billion for the last quarter, which should intensify the kerfuffle over its US price ($1000 per pill, $84,000 for a 12 week course of medication).Meanwhile, reports of its wondrous properties continue to appear in medical journals.The latest was announced this way in Bloomberg, Gilead Science Inc Solvadi, controversial because of its price, helps cure hepatitis C in people with HIV, according to researchers who say the drug has the potential to limit a top cause of ...
Source: Health Care Renewal - July 24, 2014 Category: Health Management Tags: clinical trials evidence-based medicine Gilead Sovaldi Source Type: blogs

Sovaldi, a Quantum Leap... Backwards to the Days Before Randomized Controlled Trials?
The Sovaldi (sofosbuvir - Gilead) media circus is continuing.  The New York Times just reported that sales of the new drug for hepatitis C were about $3.5 billion for the last quarter, which should intensify the kerfuffle over its US price ($1000 per pill, $84,000 for a 12 week course of medication).Meanwhile, reports of its wondrous properties continue to appear in medical journals.The latest was announced this way in Bloomberg, Gilead Science Inc Solvadi, controversial because of its price, helps cure hepatitis C in people with HIV, according to researchers who say the drug has the potential to limit a top cause of ...
Source: Health Care Renewal - July 24, 2014 Category: Health Management Tags: clinical trials evidence-based medicine Gilead Sovaldi Source Type: blogs

Senate Aging Committee Hearing on Drug Prices: Faster Generics Approval Could Cut Drug Costs
Conclusion As Senator Tom Tillis reminded his colleagues, it is important to not "cast all pharmaceutical companies in the same light," but instead focus on the few pharmaceutical companies acting as "hedge funds." There were many senators in attendance at the hearing, and many who went over their five-minute time allotment in asking questions of the witnesses. This committee in particular seems to have a laser-focus on the high cost of prescription drugs, and it is likely we will see some bills or other action from senators on the committee in the coming months. The good news is, the senators all seem to be interested ...
Source: Policy and Medicine - December 11, 2015 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs

What Experts in Law and Medicine Have to Say About the Cost of Drugs
By ANDY ORAM Pharmaceutical drug costs impinge heavily on consumers’ consciousness, often on a monthly basis, and have become such a stress on the public that they came up repeatedly among both major parties during the U.S. presidential campaign–and remain a bipartisan rallying cry. A good deal of the recent conference named Health Law Year in P/Review, at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, covered issues with a bearing on drug costs. It’s interesting to take the academic expertise from that conference–and combine it with a bit of commo...
Source: The Health Care Blog - February 2, 2017 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Andy Oram Drug Pricing Pharma Source Type: blogs

Abort, Retry, Fail - Billionaire Bill Gates Opines, Sans Evidence, on ... the Efficacy of Hepatitis C Treatment?
Conclusions So maybe Bill Gates' seemingly ill-informed apologia for the extremely high drug prices charged in the US, and his lack of understanding of the evidence about the efficacy, or lack thereof, of some of these high priced drugs is a small humorous story that indicates just the tip of the iceberg.  It appears that in our current market fundamentalist, neoliberal world, foundations may be more about promoting the commercial interests of their board members and officers than about improving the lot of humanity.  Yet for the most part they may succeed in obfuscating what they are doing through the haze of ma...
Source: Health Care Renewal - July 14, 2016 Category: Health Management Tags: conflicts of interest Gates Foundation Genentech Gilead global health health care foundations hepatitis C Sovaldi Source Type: blogs

Point-of-Care HIV Diagnostics for Low Resource Regions: Interview with Jesse Lehga, VP at Diagnostics for the Real World
DRW (Diagnostics for the Real World), a company with headquarters in San Jose, California, and Cambridge, United Kingdom, has developed the SAMBA II, a point-of-care diagnostic device for the detection of infectious diseases, including HIV and HCV, f...
Source: Medgadget - February 27, 2020 Category: Medical Devices Authors: Conn Hastings Tags: Diagnostics Exclusive Medicine Pathology Source Type: blogs

STI Guideline Updates for Pediatric Hospitalists
PHM Session: 2021 Sexually Transmitted Infection (STI) Guideline Updates: What the Pediatric Hospitalist Needs to Know Presenters: Jason Zucker, MD, Columbia University, New York, and Candice McNeil, MD, MPH, Atrium Health Wake Forest Baptist, Winston-Salem, N.C. As the assistant director of the New York City STD/HIV Prevention Training Center and co-medical director of the Southeast STD/HIV Prevention Training Center, Drs. Zucker and McNeil shared their expertise on this ever-evolving topic. As of 2020, there were more than 2 million cases of chlamydia and gonorrhea, about 130,000 cases of syphilis, and a 235% increase in...
Source: The Hospitalist - September 23, 2022 Category: Hospital Management Authors: Lisa Casinger Tags: Adolescent Medicine Clinical Guidelines Diagnostic Education HIV Lifestyle Pediatrics STIs Source Type: research

JAMA Internal Medicine —Providing Compelling, Credible, Timely, and Essential Evidence
We live in a time of breathtaking advances in biomedicine. During my lifetime, scientific breakthroughs have made previously fatal or debilitating diseases treatable with revolutionary new drugs or molecularly targeted approaches for AIDS, hepatitis, cancer, and many other conditions across the full spectrum of internal medicine. Medical discovery has also helped set the stage for the highly accelerated development of the COVID-19 vaccine —one of the greatest scientific achievements in history. In stark juxtaposition to these advances, we are facing unprecedented challenges and stressors to our health care systems. Misin...
Source: JAMA Internal Medicine - July 3, 2023 Category: Internal Medicine Source Type: research

Logical Fallacies in Defense of Aggresive Screening for and Treatment of Hepatitis C
And the hepatitis C follies continue... As we have frequently written, most recently last week, the hepatitis C screening and treatment bandwagon keeps rolling along.  There is constant public argument about the prices of treatment regimens, which approach $100,000 per patient in the US.  However, nearly all the public chatter, which seems mostly to come from corporate public relations people and marketers, investors and investment advisers, physicians with financial conflicts of interest, and pundits with little background in clinical epidemiology, seems never to question the assumption that the new drugs for he...
Source: Health Care Renewal - January 21, 2015 Category: Health Management Tags: anechoic effect evidence-based medicine hepatitis C logical fallacies Sovaldi Source Type: blogs

Praluent, the Next Expensive "Game Changer," Blockbuster," "New Hope," - But Not Yet Shown to Benefit Patients
ConclusionsThe NEJM study was accompanied by an editorial by Stone and Lloyd-Jones(2) which documented that drugs previously shown to lower cholesterol were never proved to do any good for patients, and concluded,it would be premature to endorse these drugs for widespread use before the ongoing randomized trials, appropriately powered for primary end-point analysis and safety assessment, are available. After an FDA advisory committee recommended approval of aliromucab and another PCSK9 inhibitor in June, 2015, John Mandrola entitled a Medscape article,Dear FDA: Resist the Urge on PCSK9 DrugsHis reasons included lack o...
Source: Health Care Renewal - August 5, 2015 Category: Health Management Tags: aliromucab evidence-based medicine health care prices manipulating clinical research PCSK9 inhibitor Praluent Regeneron Sanofi-Aventis Source Type: blogs

Largest Fraud Takedown Announced by AG Sessions
On Thursday, July 13, 2017, United States Attorney General Jeff Sessions and Department of Health and Human Services (HHS) Secretary Tom Price, M.D., announced the largest ever health care fraud enforcement action by the Medicare Fraud Strike Force. The action charged 412 defendants across forty-one federal districts for their alleged participation in health care fraud schemes involving $1.3 billion in false billings. The 412 defendants include 115 doctors, nurses, and other licensed professionals. Of the 412 defendants, over 120 of them were charged for their roles in prescribing and distributing opioids and other danger...
Source: Policy and Medicine - July 19, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs